StampPump:Proof of Principle for a Disruptive Insulin Delivery Technology
Award amount
$276,277Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Thermalin Inc.
- Proposal award date
- 2019-04-15
- Contract end date
- 2020-03-31
- UEI
- NZ8VXJXMMMW6
- Solicitation number
- PA18-574
- Topic code
- 200
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Disrupting Insulin Delivery with a Novel, Stabilized Insulin that is Ultra-rapid at U100 or U500
- StampPump: a Postage-Stamp Sized Autonomous Glycemic Control Mechanism for Patients Suffering Glycemic Abnormalities as a Result of Critical Illnesses
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment
Research funding history
3 SBIR/STTR records share this UEI (2019–2020). Reported award amounts total $3,494,632. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense